Chemistry:Cebranopadol
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Pharmacokinetic data | |
| Elimination half-life | ~4.5 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C24H27FN2O |
| Molar mass | 378.491 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Cebranopadol (developmental code GRT-6005) is an opioid analgesic of the benzenoid class which is currently under development internationally by Grünenthal, a Germany pharmaceutical company, and its partner Depomed, a pharmaceutical company in the United States , for the treatment of a variety of different acute and chronic pain states.[1][2][3] As of November 2014, it is in phase III clinical trials.
Cebranopadol is unique in its mechanism of action as an opioid, binding to and activating all four of the opioid receptors; it acts as a full agonist of the μ-opioid receptor (Ki = 0.7 nM; EC50 = 1.2 nM; IA = 104%), and δ-opioid receptor (Ki = 18 nM; EC50 = 110 nM; IA = 105%), and as a partial agonist of the nociceptin receptor (Ki = 0.9 nM; EC50 = 13.0 nM; IA = 89%) and κ-opioid receptor (Ki = 2.6 nM; EC50 = 17 nM; IA = 67%).[1] The EC50 values of 0.5–5.6 µg/kg when introduced intravenously and 25.1 µg/kg after oral administration.[4]
Cebranopadol shows highly potent and effective antinociceptive and antihypertensive effects in a variety of different animal models of pain.[1] Notably, it has also been found to be more potent in models of chronic neuropathic pain than acute nociceptive pain compared to selective μ-opioid receptor agonists.[1] Relative to morphine, tolerance to the analgesic effects of cebranopadol has been found to be delayed (26 days versus 11 days for complete tolerance).[1] In addition, unlike morphine, cebranopadol has not been found to affect motor coordination or reduce respiration in animals at doses in or over the dosage range for analgesia.[1] As such, it may have improved and prolonged efficaciousness and greater tolerability in comparison to currently available opioid analgesics.[1]
As an agonist of the κ-opioid receptor, cebranopadol may have the capacity to produce psychotomimetic effects, dysphoria, and other adverse reactions at sufficiently high doses, a property which could potentially limit its practical clinical dosage range, but would likely reduce the occurrence of patients taking more than their prescribed dose.[5]
See also
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist". The Journal of Pharmacology and Experimental Therapeutics 349 (3): 535–548. June 2014. doi:10.1124/jpet.114.213694. PMID 24713140.
- ↑ "Discovery of a Potent Analgesic NOP and Opioid Receptor Agonist: Cebranopadol". ACS Medicinal Chemistry Letters 5 (8): 857–862. August 2014. doi:10.1021/ml500117c. PMID 25147603.
- ↑ "Cebranopadol: a first in-class example of a nociceptin/orphanin FQ receptor and opioid receptor agonist". British Journal of Anaesthesia 114 (3): 364–366. March 2015. doi:10.1093/bja/aeu332. PMID 25248647.
- ↑ "Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist". The Journal of Pharmacology and Experimental Therapeutics 349 (3): 535–548. June 2014. doi:10.1124/jpet.114.213694. PMID 24713140.
- ↑ "Psychotomimesis mediated by kappa opiate receptors". Science 233 (4765): 774–776. August 1986. doi:10.1126/science.3016896. PMID 3016896. Bibcode: 1986Sci...233..774P.
External links
 |  |
